Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05060016 2025-12-22

DeLLphi-301

Phase 2 Active not recruiting

222 enrolled 1 FDA

Thoracic

Small Cell Lung Carcinoma

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Phase 2 Active not recruiting

55 enrolled

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04701307 2025-12-15

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Phase 2 Active not recruiting

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04745689 2025-12-10

TAZMAN

Phase 2 Active not recruiting

31 enrolled 15 charts

Thoracic

Small Cell Lung Carcinoma

NCT04010357 2025-12-02

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Phase 2 Active not recruiting

14 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03672773 2025-11-10

TRIO-US L-07

Phase 2 Active not recruiting

35 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT01638546 2025-10-29

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Active not recruiting

97 enrolled 12 charts

Thoracic

Small Cell Lung Carcinoma

NCT04397003 2025-10-22

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Phase 2 Active not recruiting

6 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04702880 2025-10-08

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Phase 2 Active not recruiting

120 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04472949 2025-10-01

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Phase 2 Active not recruiting

46 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05363280 2025-09-23

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

Phase 2 Active not recruiting

36 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04553133 2025-08-28